Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jul 25, 2018 |
referred to health |
Assembly Bill A11279
2017-2018 Legislative Session
Sponsored By
FAHY
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
2017-A11279 (ACTIVE) - Details
2017-A11279 (ACTIVE) - Summary
Requires dihydropyrimidine dehydrogenase deficiency testing prior to fluoropyrmidine or other antimetabolite treatment; requires policies and contracts of insurance to include coverage for dihydropyrimidine dehydrogenase deficiency testing; provides for dihydropyrimidine dehydrogenase deficiency testing under the medical assistance program.
2017-A11279 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 11279 I N A S S E M B L Y July 25, 2018 ___________ Introduced by COMMITTEE ON RULES -- (at request of M. of A. Fahy) -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to requiring dihydro- pyrimidine dehydrogenase deficiency testing for certain individuals with cancer; to amend the insurance law, in relation to requiring policies and contracts of insurance to include coverage for dihydropy- rimidine dehydrogenase deficiency testing; and to amend the social services law, in relation to the provision of dihydropyrimidine dehyd- rogenase deficiency testing under the medical assistance program THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. The public health law is amended by adding a new section 2400-a to read as follows: § 2400-A. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY TESTING. 1. FOR PURPOSES OF THIS SECTION THE FOLLOWING TERMS SHALL HAVE THE FOLLOWING MEANINGS: (A) "ANTIMETABOLITES" MEANS A SUBSTANCE THAT INTERFERES WITH THE NORMAL METABOLIC PROCESSES WITHIN CELLS, TYPICALLY BY COMBINING WITH ENZYMES. (B) "DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY" MEANS A CONDITION IN WHICH THE BODY CANNOT BREAK DOWN THE NUCLEOTIDES THYMINE AND URACIL. (C) "FLUOROPYRMIDINE" MEANS A GROUP OF SUBSTANCES USED TO TREAT CANCER THROUGH CHEMOTHERAPY. 2. EVERY PHYSICIAN OR OTHER AUTHORIZED PRACTITIONER WHO PROVIDES FLUO- ROPYRMIDINE OR OTHER ANTIMETABOLITES TO INDIVIDUALS DIAGNOSED WITH CANCER SHALL TEST FOR DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY PRIOR TO SUCH TREATMENT. § 2. Subparagraph (A) of paragraph 12-a of subsection (i) of section 3216 of the insurance law, as amended by chapter 12 of the laws of 2012, is amended to read as follows: (A) Every policy delivered or issued for delivery in this state that provides medical, major medical, or similar comprehensive-type coverage and provides coverage for prescription drugs and also provides coverage for cancer chemotherapy treatment shall provide coverage for prescribed, EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.